|

Aumolertinib Clinical Trials

3 actively recruiting trials

Also known as: Almonertinib, Almonertinib Mesilate Tablets, HS-10296

Pipeline

Phase 1: 1Phase 3: 1Phase 2/3: 1

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.1
  • Hansoh BioMedical R&D Company1

Indications

  • Lung Cancer3
  • Cancer3
  • Non Small Cell Lung Cancer2
  • Non-Squamous Non-Small Cell Lung Cancer1

Other3 trials

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer
Phase 1
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Phase 2/3
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.